Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | TEST |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
info here |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all UCB Partners with Oxford UniversityUCB has entered into a research and development partnership with Oxford University in Neurology and Immunology areas. UCB will provide 3.6 million pounds to Oxford scientists over a period of three year to conduct research. View all |
No EVENTS for listing |
No Job Posts |
